<DOC>
	<DOCNO>NCT02684279</DOCNO>
	<brief_summary>Binge Eating Disorder Extension Study .</brief_summary>
	<brief_title>Dasotraline Binge Eating Disorder Extension Study</brief_title>
	<detailed_description>This Phase 3 , 12 month , multicenter , open-label , flexibly-dosed , safety study adult Binge Eating Disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<criteria>Completion treatment period dasotraline core study ( ie , SEP360 221 ) treatment BED . Subject agree participate providing write informed consent willing able comply protocol , opinion investigator . Subject take medication study drug purpose control BED symptom core study . Female subject must negative urine pregnancy test open label ( OL ) Baseline ; female postmenopausal ( define least 12 month spontaneous amenorrhea ) undergone hysterectomy bilateral oophorectomy exempt pregnancy test . Female subject childbearing potential male subject female partner childbearing potential must agree use effective medically acceptable form birth control ( see Section 22 , Appendix III ) throughout study period . Note : Continued use effective medically acceptable form birth control recommend 30 day study completion . Subject judge investigator suitable participation 12 month clinical trial involve openlabel dasotraline treatment . Subject read well enough understand informed consent form subject material . Subject consider investigator imminent risk suicide , injury self others , damage property . Subject answer `` yes '' `` suicidal ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) C SSRS assessment OL Baseline . Subjects answer `` yes '' question must refer Investigator follow evaluation . Subject clinically significant abnormality include physical examination , vital sign , ECG , laboratory test investigator consultation medical monitor considers inappropriate allow participation study . Subject positive urine drug screen ( UDS ) breath alcohol test OL Baseline . Subject breastfeeding . Subject high risk noncompliance investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>